Feeding the Threat

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Here’s what you missed this week on Managed Healthcare Executive.

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell transplant.